6533b850fe1ef96bd12a8250

RESEARCH PRODUCT

Subcutaneous trastuzumab therapy for HER2-positive early breast cancer in the routine clinical practice: First interim analysis of the National Non-Interventional Study (NIS) HerSCin.

Andrea DistelrathSherko KümmelStella KeitelKerstin Luedtke-heckenkampMarcus SchmidtAntonia Ruf-doerdelmannSabine SchmatlochJuergen Wacker

subject

OncologyCancer Researchmedicine.medical_specialtybusiness.industryInterim analysisSurgeryOncologyTrastuzumabInternal medicineNon interventionalmedicineRoutine clinical practiceskin and connective tissue diseasesbusinessmedicine.drugEarly breast cancer

description

581Background: In 2013 a subcutaneous (SC) formulation of trastuzumab (T) was approved based on non-inferiority to intravenous (IV) T as proven in the HannaH trial. So far no data from the routine ...

https://doi.org/10.1200/jco.2016.34.15_suppl.581